ALK and non-small cell lung carcinoma: During the phase III ALESIA study, researchers evaluated alectinib as a treatment for crizotinib in Eastern Asian patients with untreated ALK-positive NSCLC and determined that alectinib reduced the risk for progression or death (HR 0.22, 95% CI 0.13–0.38) [13].